Get Connected:


Latest News

Diabetes Biomarkers Among Patients with Obesity Discovered
A transcription factor may contribute to adipose fibrosis and increase the risk of type 2 diabetes among patients with obesity.
Top news of the day from the health care landscape.
A look at last week's top stories in the world of pharmacy.
The federal government previously ruled that dual eligibles would need to use the Medicare part D program for prescriptions preferentially.
New research indicates there are distinct subgroups of osteoarthritis that can impact treatment.
Top news of the day from across the health care landscape.
Researchers are developing novel treatments to support weight management, although limited data supports their use in diabetes. 
States are now allowed to require able-bodied, working-age Medicaid beneficiaries to be employed or participate in community engagement activities.
View More >

From the Journals

Focusing on cost alone could diminish the vital service aspects behind successfully caring for a patient in a specialty pharmacy.
In a review of publicly reported diabetes quality measures for Medicaid fee-for-service, overall reporting was low and reports of outcomes measures were rarely available.
This study assessed the impact of initiating hyaluronic acid injections on pain management pharmacotherapies utilization patterns in patients with knee osteoarthritis.
Initiation of treatment with guideline-recommended medications within 60 days of fibromyalgia diagnosis was associated with immediate annual healthcare cost savings.
The findings of a retrospective study suggest that timing of heart failure (HF)-related pharmacotherapy following a HF-related encounter has potential implications on subsequent healthcare costs.
Many healthcare stakeholders are concerned that pharmacy benefit managers use perverse incentives that work against healthcare goals, such as improved outcomes and lower costs.
For patients with psoriasis and/or psoriatic arthritis, actual-to-expected dosing ratios and costs were lower for etanercept than for ustekinumab.
Upcoming Partner Events